Zhao Yongqing, Zhu Weixiong, Dong Shi, Zhang Hui, Zhou Wence
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, China.
J Gastroenterol Hepatol. 2025 Feb;40(2):355-366. doi: 10.1111/jgh.16873. Epub 2025 Jan 8.
Pancreatic and hepatobiliary cancers are increasing in prevalence and contribute significantly to cancer-related mortality worldwide. Emerging therapeutic approaches, particularly immunotherapy, are gaining attention for their potential to harness the patient's immune system to combat these tumors. Understanding the role of immune cells in the tumor microenvironment (TME) and their metabolic reprogramming is key to developing more effective treatment strategies. This review aims to explore the relationship between immune cell function and glucose metabolism in the TME of pancreatic and hepatobiliary cancers.
This review synthesizes current research on the metabolic adaptations of immune cells, specifically focusing on glucose metabolism within the TME of pancreatic and hepatobiliary cancers. We examine the mechanisms by which immune cells influence tumor progression through metabolic reprogramming and how these interactions can be targeted for therapeutic purposes.
Immune cells in the TME undergo significant metabolic changes, with glucose metabolism playing a central role in modulating immune responses. These metabolic shifts not only affect immune cell function but also influence tumor behavior and progression. The unique metabolic features of immune cells in pancreatic and hepatobiliary cancers provide new opportunities for targeting immune responses to combat these malignancies more effectively.
Understanding the complex relationship between immune cell glucose metabolism and tumor progression in the TME of pancreatic and hepatobiliary cancers offers promising therapeutic strategies. By modulating immune responses through targeted metabolic interventions, it may be possible to improve the efficacy of immunotherapies and better combat these aggressive cancers.
胰腺癌和肝胆癌的发病率正在上升，在全球癌症相关死亡率中占很大比例。新兴的治疗方法，尤其是免疫疗法，因其利用患者免疫系统对抗这些肿瘤的潜力而受到关注。了解免疫细胞在肿瘤微环境（TME）中的作用及其代谢重编程是制定更有效治疗策略的关键。本综述旨在探讨胰腺癌和肝胆癌TME中免疫细胞功能与葡萄糖代谢之间的关系。
本综述综合了目前关于免疫细胞代谢适应性的研究，特别关注胰腺癌和肝胆癌TME中的葡萄糖代谢。我们研究了免疫细胞通过代谢重编程影响肿瘤进展的机制，以及如何针对这些相互作用进行治疗。
TME中的免疫细胞发生显著的代谢变化，葡萄糖代谢在调节免疫反应中起核心作用。这些代谢转变不仅影响免疫细胞功能，还影响肿瘤行为和进展。胰腺癌和肝胆癌中免疫细胞的独特代谢特征为靶向免疫反应以更有效地对抗这些恶性肿瘤提供了新机会。
了解胰腺癌和肝胆癌TME中免疫细胞葡萄糖代谢与肿瘤进展之间的复杂关系提供了有前景的治疗策略。通过有针对性的代谢干预调节免疫反应，可能提高免疫疗法的疗效并更好地对抗这些侵袭性癌症。
